1984 Volume 32 Issue Supplement4 Pages 305-315
Basic and clinical studies were made on a new combination of the drugs, SBT/CPZ, i.e. Cefoperazone (CPZ) and sulbactam (STB) 1:1.
The results obtained were as follows:
1) Antibacterial activity in vitro:
The activity of SBT/CPZ was found to be much more active against gram-negative bacilli, especially against Proteus (both indole positive and negative species) and Serratia than CPZ alone. The MIC of Oralone were 25-50μg/ml against most of the gram negative bacilli.
2) Distribution in the rat's body:
100mg/ml of SBT/CPZ was administered intramuscularly to rats, and the tissue concentrations of each drug were serially estimated: SBT and CPZ showed similar pharmakinetic patterns. The order of their tissue concentrations were liverkidnies>blood>lungs>spleen>muscles.
3) Clinical trials
Eight patients with various complicated infections were treated with 2-4g SBT/CPZ per day by drip infusion: One of them turned out to be myeoplasmic pneumoniae and was excluded from the evaluation. Good responses were obtained in 4 our of the 7 cases, while one of the other three patients, having ulcerative stomatitis, showed bacterial substitution by the treatment.
As to the side effects, a drug fever occured in one of the cases after seven days treatment. No abnormal laboratory findings were observed.
